Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

HENDERSON, Nev.--Sep. 8, 2020-- Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences:
  • Rodman & Renshaw 22nd Annual Global Investment Conference, Sponsored by H.C. Wainwright, Monday, September 14, 2020 at 2:00 p.m. ET.
  • Cantor Virtual Global Healthcare Conference, Thursday, September 17, 2020 at 10:40 a.m. ET.
A live webcast of the presentations will be available from the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations with a replay available shortly after each event.

About Spectrum Pharmaceuticals, Inc. 

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future.

Robert Uhl
Managing Director, Westwicke ICR
858.356.5932
robert.uhl@westwicke.com

Kurt Gustafson
Chief Financial Officer
949.788.6700
InvestorRelations@sppirx.com

Source: Spectrum Pharmaceuticals

Related Posts

Subscribe Our Newsletter